Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Keltner Llew
   2. Issuer Name and Ticker or Trading Symbol
Raptor Pharmaceutical Corp [RPTP] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O RAPTOR PHARMACEUTICAL CORP., 5 HAMILTON LANDING, SUITE 160		 3. Date of Earliest Transaction (Month/Day/Year)
11/07/2013
(Street)

NOVATO, CA 94949		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/07/2013(1)   M   10,000 A $ 3.3 10,000 D  
Common Stock 11/07/2013(1)   S   9,500 D $ 14.011 (6) 500 D  
Common Stock 11/07/2013(1)   S   500 D $ 14.804 (7) 0 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock options (right to buy) $ 3.3 11/07/2013(1)   M     10,000 03/30/2010(2) 09/30/2019 Common Stock 10,000 $ 0 20,961 (8) D  
Stock options (right to buy) $ 2.02             03/09/2010(2) 03/08/2020 Common Stock 13,203   13,203 (8) D  
Stock options (right to buy) $ 2.97             03/01/2011(3) 10/11/2020 Common Stock 30,000   30,000 (8) D  
Stock options (right to buy) $ 3.54             11/22/2010(4) 11/21/2020 Common Stock 90,000   90,000 (8) D  
Stock options (right to buy) $ 5.13             12/22/2011(2) 09/21/2021 Common Stock 30,000   30,000 (8) D  
Stock options (right to buy) $ 5.13             03/22/2012(5) 09/21/2021 Common Stock 90,000   90,000 (8) D  
Stock options (right to buy) $ 5.49             12/25/2012(2) 09/24/2022 Common Stock 50,000   50,000 (8) D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Keltner Llew
C/O RAPTOR PHARMACEUTICAL CORP.
5 HAMILTON LANDING, SUITE 160
NOVATO, CA 94949		   X      

Signatures

 /s/ Kim R. Tsuchimoto, Raptor Pharmaceutical Corp., Attorney-in-fact   11/12/2013
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 14, 2013.
(2) Fully vested and exercisable.
(3) Stock options vest starting on September 1, 2010, 6/48ths on February 28, 2011 and 1/48th per month thereafter.
(4) Stock option vests 25% immediately and 75% pro rata over 36 months.
(5) Stock options vest 6/48ths on March 22, 2012 and 1/48th per month thereafter.
(6) This transaction was executed in multiple trades at prices ranging from $13.55 to $14.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(7) This transaction was executed in multiple trades at prices ranging from $14.74 to $14.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(8) The shares listed as owned in column 9 represent the total shares for each respective option. Previous reports reflected aggregate amounts of option shares in column 9. The holding lines included on this Form 4 are included solely to correct the breakdown of shares among various stock options and are not meant to reflect any change in beneficial ownership of option shares other than those reported as a transaction on this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.